1. Home
  2. PXLW vs IMMP Comparison

PXLW vs IMMP Comparison

Compare PXLW & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pixelworks Inc.

PXLW

Pixelworks Inc.

N/A

Current Price

$5.50

Market Cap

35.2M

Sector

Technology

ML Signal

N/A

Logo Immutep Limited

IMMP

Immutep Limited

N/A

Current Price

$3.42

Market Cap

31.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PXLW
IMMP
Founded
1997
1987
Country
United States
Australia
Employees
163
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.2M
31.5M
IPO Year
2000
2012

Fundamental Metrics

Financial Performance
Metric
PXLW
IMMP
Price
$5.50
$3.42
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 383.9K
25.5K
Earning Date
11-11-2026
09-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 11.77
N/A
Revenue
★ $693,000.00
N/A
Revenue This Year
$87.59
N/A
Revenue Next Year
$76.92
N/A
P/E Ratio
$0.49
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.80
$0.26
52 Week High
$7.59
$5.36

Technical Indicators

Market Signals
Indicator
PXLW
IMMP
Relative Strength Index (RSI) 47.52 56.09
Support Level $5.43 $3.06
Resistance Level $6.28 $3.55
Average True Range (ATR) 0.51 0.33
MACD 0.13 -0.01
Stochastic Oscillator 25.09 62.07

Price Performance

Historical Comparison
PXLW
IMMP

About PXLW Pixelworks Inc.

Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.

About IMMP Immutep Limited

Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.

Share on Social Networks: